Interleukin 1 (IL-1) possesses multiple biological activities that may be blocked selectively by different inhibitors. Some known inhibitors block the lymphocyte activating factor (LAF/IL-1) but not the mononuclear cell factor (MCF/IL-1) measured by its capacity to stimulate prostaglandin E2 (PGE2) and colingenase production. The presence of IL-1 in vivo may be difficult to detect due to the presence of inhibitor(s) and the level of the inhibitor(s) may vary depending upon pathological conditions. We have found that urine from three patients with monocytic leukemia (M5) contained high levels of inhibitor(s) of MCF/II-1, whereas urine of normal subjects did not contain significant amounts. Urine from two patients with other blood neoplasic diseases also contained little inhibitory activity. The MCF/IL-1 inhibitor(s), which also acts on human recombinant IL-1 ft, is -25-35 kD, is not retained on concanavalin A-Sepharose column and can be partially destroyed with urea and boiling. At this stage of the purification the fraction containing the MCF/IL-1 inhibitor(s) also inhibits the LAF/IL-1 assay. However, this inhibitor(s) is probably distinct from other inhibitors already described.
Introduction
1. Abbreviations used in this paper: Con A, concanavalin A; DME, Dulbecco's modified Eagles medium; hrIL-l ,B, human recombinant IL-I f,; IL-1, interleukin 1; LAF, lymphocyte-activating factor; MCF, mononuclear cell factor; PGE2, prostaglandin E2-glandin E2 (PGE2) and collagenase, both of which reflect mechanisms of tissue destruction (4) (5) (6) (7) (8) . IL-1 has been found in synovial fluid (9, 10) , serum (11, 12) , and urine (13, 14) . However, the control of IL-I activities and its regulation in vivo is poorly understood. Inhibitors of LAF/IL-1 have been revealed in urine (13, 14) , serum (15) , and cell culture supernatant (16) (17) (18) (19) , but no in vivo inhibitory activity against MCF/IL-l has been described as yet. We now report MCF/IL-l activities ('-67, -35, and 17 kD) and MCF/IL-l inhibitor(s) (-25 kD) in urine from patients with monocytic leukemia. These findings may have important implications since such inhibition could counteract the stimulation of collagenase and PGE2 and suggest a possible balance in regulation of tissue destruction.
Methods
Patients and urine collection. The diagnosis of acute monocytic leukemia (M5 of the French American British classification) (20) was established in three patients. B.M. was a 44-yr-old woman hospitalized for fever without infection. H.P. was a 74-yr-old man hospitalized for high fever and pneumonia. F.C. was a 41-yr-old woman presenting with loss of weight, high fever, and asthenia without infection. Two other patients with neoplasic diseases and high fever (T lymphoma and chronic myelomonocytic leukemia) and five normal donors without fever were also investigated. Urine (400 ml) was collected before any treatment. After addition of 20 ug/ml of gentamycin, urine was dialyzed at 4°C against bidistilled water (3.5 kD, Spectrapore, Spectrum Medical Industries, Inc., Los Angeles, CA). Urine was then concentrated -20-fold with Aquacide II (Calbiochem-Behring Corp., La Jolla, CA), centrifuged at 9,000 g for 30 min at 4°C and stored at -20°C.
MCF/IL-I preparation. MCF/IL-1 was generated in the supernatant of concanavalin A (Con A, 0.1 ,ug/ml; Pharmacia Fine Chemicals, Piscataway, NJ) and phytohemagglutinin (0.1 g/ml Wellcome Research Laboratories, Kent, England) stimulated peripheral blood mononuclear cells (2.106 cells/ml, 72 h in RPMI 1640, 10% fetal calf serum, FCS). The supernatant was purified on ultrogel AcA54 gel filtration monitored by the collagenase-and PGE2-stimulating activity (21). Using human recombinant IL-I , as a standard, the activity of the MCF/IL-I preparation in this study was equivalent to 100 pg/ml or 2 U in the C3H/HeJ mouse thymocyte proliferation assay. One unit represents the 50% stimulation in the assay (6 No MCF/IL-l activity could be detected at any dilution ( Fig.  1 ). In contrast a marked inhibition of PGE2-and collagenasestimulating activity induced by a partially purified preparation of MCF/IL-l was observed up to a dilution of 1:160. This inhibition was partially overcome by increasing amounts ofMCF/ IL-1. Fibroblast number and morphology were unchanged and viability in cultures exposed to urine and/or to MCF/IL-1 was >95% by trypan blue dye exclusion test.
Biochemical characterization. To determine whether MCF/ IL-I activity can be masked by an inhibitor, urine from two patients (B;M. and H.P.) was fractionated on ultrogel AcA54 gel. Eluted fractions were tested in presence of a constant concentration of MCF/IL-1. MCF/IL-1 activity was eluted in two major peaks -67 kD, -35 kD (Fig. 2 A) and one additional peak 17 kD for H.P. (Fig. 2 B) . The same fractions that exhibited activity in presence of exogenous MCF/IL-l were found to effectively contain MCF/IL-l when tested in the absence of exogenous MCF/IL-1 (Fig. 2 A) . In contrast, a significant inhibition of MCF/IL-l activity was found close to the soybean taining inhibitory activity were treated with 8 M urea or boiled for 1O min. These two treatments reduced the inhibitory activity by 54.5 and 78.6%, respectively (Table I) . Patient study. The urine from three patients with monocytic leukemia, two patients with blood neoplasic diseases and five normal subjects were compared for MCF/IL-l and MCF/IL-l inhibitory activity. The dialyzed urines and the chromatographed fractions containing the peak ofthe MCF/IL-l activity or MCF/ IL-l inhibitory activity were measured in percentages of stimulation of PGE2 production by fibroblasts and in percentages of inhibition of the activity of MCF/IL-l stimulated fibroblasts. MCF/IL-l activity was tested in the absence ofadditional MCF/ IL-I (Table II) . All urine from patients with monocytic leukemia showed a marked inhibitory activity in crude dialyzed and chromatographed material as well as a stimulatory activity when chromatographed. Urines from other patients and normal subjects exhibited significantly lower activities in both inhibitory and stimulatory effects. with DME, 10o% FCS containing purified MCF/IL-1. After 72 h incubation on fibroblasts media were removed and assayed for PGE2 and collagenase. Values represent mean±SEM (n = 3).
and purified material (13, (14) (15) (16) (17) (18) (19) (20) (21) (22) . However, these inhibitors found in vivo did not seem to affect MCF/IL-1 as defined by PGE2 production-stimulating activity (23). In contrast, in a preliminary report, we found that urine from a monocytic leukemia patient (M5) contained inhibitor(s) for MCF/IL-1 (24) . A similar biological action has recently also been described in an in vitro study in which an inhibitor of MCF/IL-l and LAF/IL-l was found to be produced by monocytes exposed to adherent immune complexes (25) . We now report that unfractionated urines from three patients with monocytic leukemia (M5) contain high levels of inhibitors for MCF/IL-L. In comparison, two other groups of individuals were also studied: two febrile patients with other neoplasic diseases (T lymphoma and chronic myelomonocytic leukemia) and five normal subjects. It is interesting that the same type of observation was made in these two groups although the inhibition/ stimulation measured was much lower as compared to that of the MS patients. Among the five normal subjects only one showed a slight inhibitory activity (10%). At the present stage of purification only semiquantitative measurements have been performed. In the unfractionated urine of our patients we did not detect the presence of spontaneous MCF/IL-1 activity but such an activity was very strong following gel filtration. In addition to the absence ofinhibitory activity against MCF/IL-l by the urine-derived LAF/IL-l inhibitor described by others (23) there was already evidence that the LAF/IL-l inhibitor(s) was not active in the MCF/IL-I bioassay. It has been shown that the production of LAF/IL-l was hampered by inhibitors in supernatants of U937 monocytic cell line, but in contrast the MCF/ IL-l activity was not overcome by these LAF/IL-1 inhibitors (16) (17) (18) . This indicates that the urinary inhibitor(s) found in our study is different from the one produced by U937 cells or described in urine (23) or liver extracts (26) . It is interesting to note that the urinary and the liver homogenate inhibitor of LAF/IL-I inhibitors previously described (23, 26) both have a PGE2-stimulating activity. In addition l-antitrypsin has been shown to modulate the biological activity of LAF/IL-1, although inhibition requires high concentrations ofa1-antitrypsin (2-4 mg/ml) (27) . We have not found inhibition of MCF/IL-1 by adding 0.2 and 2 mg/ml of a1-antitrypsin to our preparations.
To determine whether the urinary MCF/IL-I inhibitor(s) is a molecule similar to other glycoproteins with inhibitory activity in the lymphocyte proliferation assay (22) a 40-80% ammonium sulfate-precipitated urine was chromatographed on a Con A-Sepharose gel. The inhibitory activity was not retained on the gel in contrast to uromodulin. The molecular weight (85 kD) also differs from our inhibitor. The MCF/IL-activity was not revealed by this chromatography step indicating that MCF/ IL-l coelutes with the inhibitor(s). When the inhibitory fractions ofthe Con A-Sepharose column were fractionated on an ultrogel AcA54 the MCF/IL-l activity was then revealed (data not shown). To determine whether the inhibitor(s) was a protein, the AcA54 inhibitory fraction was treated with 8 M urea or boiled. The inhibitory activity was partially destroyed indicating that the inhibitor(s) was very resistant and heat stable. Despite the inconclusive data of Table II, the molecular weight suggests the existence of a protein moiety.
We have also observed inhibitory activity in a low molecular weight range (<5,000, data not shown). This may be due to other substances or breakdown products. At this stage of the purification the fraction containing the MCF/IL-l inhibitor(s) also contains LAF/IL-1 inhibitor(s). The inhibitor(s) is also acting in presence of human recombinant IL-1 f3.
Our observations taken together with the information from others suggest the existence of different inhibitors of different IL-I biological activities. Only after purification and precise characterization of the inhibitor(s) will it be possible to analyze and quantify the kinetics and balance of MCF/IL-l and MCF/ IL-l inhibitors in urine that might mirror local events in tissues.
This observation represents to our knowledge the first description of an in vivo human natural inhibitor(s) of MCF/IL-l activity assessed by the stimulation ofcollagenase and PGE2 production by fibroblasts and synovial cells. It remains to be established at which cellular level the inhibition takes place. Recent experiments performed with this inhibitor suggest that the MCF/ IL-l inhibition occurs at the receptor level (P. Seckinger, J. Lowenthal, K. Williamson, J.-M. Dayer, and R. MacDonald. Manuscript in preparation). This inhibitor(s) therefore could be considered as an important natural molecule for modulating connective tissue destruction.
